Tyrosine kinase inhibitorFDA-approvedFirst-line
Alectinib
How it works
Blocks the anaplastic lymphoma kinase (ALK) on cancer cells, preventing growth signals.
Cancer types
Lung Cancer— ALK-positive
Efficacy
In clinical trials, around 80% of ALK-positive patients achieved an objective response, with a median progression-free survival of approximately 11.2 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Rare Genetic Changes Found in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Rare Lung Cancer Mutation Responds to New Treatment | Lung Cancer | lab-study | The patient achieved a durable partial response to lorlatinib (progression-free survival > 15 months). | Source → |
| Alectinib Improves Lung Cancer Outcomes in Some Patients | Lung Cancer | phase-3 | Alectinib improved progression-free survival (HR 0.41, 95%CI 0.31-0.55, p < 0.001) compared to crizotinib. | Source → |
| Rare Side Effect of Cancer Treatment Alectinib | Lung Cancer | observational | — | Source → |
| Alectinib Shows Better Results Than Ceritinib in Lung Cancer Study | Lung Cancer | observational | First-line alectinib demonstrated superior intracranial disease control compared with ceritinib (iDCR 97.6% vs. 83.3%, p = 0.026) | Source → |
| Cancer Drugs Cross Placenta in Lab Study | Lung Cancer | lab-study | — | Source → |
| Alectinib's Effectiveness in Lung Cancer Fades Over Time | Lung Cancer | review | — | Source → |
| Alectinib's Side Effects Linked to Biotin Deficiency | Lung Cancer | lab-study | — | Source → |
| Combining Alectinib and Cobimetinib to Treat Advanced Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Lorlatinib Cost-Effective for Lung Cancer Patients in Italy | Lung Cancer | phase-3 | Lorlatinib provided higher benefits (+2.01 life-years; +1.66 quality-adjusted life-years) at lower costs (-€19,210 per patient) compared to alectinib. | Source → |
| Alectinib and Genetic Variations in Non-Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Researchers Explore How Immune Cells Affect Lung Cancer Treatment | Lung Cancer | observational | Progression-free survival on alectinib appeared longer in patients with high than in those with low CD8A expression; however, this difference was not statistically conclusive (HR, 0.49 [95% CI, 0.18-1.35]). | Source → |
| Study of Alectinib as Adjuvant Therapy for Early Stage Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Alectinib Shows Benefit in Early-Stage Lung Cancer Treatment | Lung Cancer | phase-3 | Patients receiving alectinib had longer DFS versus those who received chemotherapy. | Source → |
| Rare Cancer Mutation Responds to Alectinib Treatment | Lung Cancer | observational | The patient achieved a durable response with a progression-free survival of nearly four years. | Source → |
| Alectinib Treatment Effective for Some Lung Cancer Patients | Lung Cancer | observational | The median maximum tumor reduction rates were 90.5% for patients with V1, 63.4% for patients with V2, and 98.0% for patients with V3. | Source → |
| Alectinib Therapy for Lung Cancer: A Single Case Study | Lung Cancer | observational | — | Source → |
| Woman with Lung Cancer Achieves Long-Term Remission with Personalized Treatment | Lung Cancer | observational | — | Source → |
| Comparing Two Cancer Treatments in Lung Cancer Patients | Lung Cancer | observational | The 3-year progression-free survival rate was 51.5% for brigatinib and 62.1% for alectinib. | Source → |
| Researchers Report a Rare Case of Cancer Remission in Stage IV Lung Cancer Patient | Lung Cancer | observational | — | Source → |
| Combining Cancer Treatments Increases Risk of Lung Damage | Lung Cancer | observational | — | Source → |
| Alectinib Shows Longer Survival in Asian Patients with Advanced Lung Cancer | Lung Cancer | phase-3 | Median progression-free survival was 41.6 months with alectinib versus 11.1 months with crizotinib. | Source → |
| Rare Liver Problem in Lung Cancer Patients Taking Alectinib | Lung Cancer | observational | — | Source → |
| Comparing Chemotherapy and Alectinib for Lung Cancer Treatment | Lung Cancer | meta-analysis | — | Source → |
| Rare Lung Cancer Patient Responds to Targeted Therapies | Lung Cancer | observational | Alectinib achieved a nearly complete response for lung and brain lesions. | Source → |
| Long-term Survival Benefits of Sequential Cancer Treatment in China | Lung Cancer | observational | Estimated 5-year OS was 68.6% in the overall population. | Source → |
| Elderly Lung Cancer Patient Responds to Alternative Treatment | Lung Cancer | observational | He had a 60% reduction in targeted pulmonary, bone and node lesions. | Source → |
| Rare Side Effect of Cancer Treatment Identified | Lung Cancer | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.